Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (DUET)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Retrophin, Inc.
ClinicalTrials.gov Identifier:
NCT01613118
First received: June 4, 2012
Last updated: June 17, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2019
  Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)